Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neuroendocrine Tumors 5Neoplasms 5Carcinoid Tumor 5Gastro-enteropancreatic neuroendocrine tumor 3Diarrhea 3Carcinoma 3Acromegaly 3Colorectal Neoplasms 2Thymoma 1Rectal Neoplasms 1Pituitary Neoplasms 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Malignant Carcinoid Syndrome 1Intestinal Obstruction 1Disease 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Adenoma, Islet Cell 1

Interventions

Carboplatin 13Paclitaxel 8Bevacizumab 7Gemcitabine 4130-nm albumin-bound paclitaxel 4liposomal doxorubicin 3relacorilant 2pembrolizumab 2nintedanib 2epothilone B 2Drug Therapy 2Albumin-Bound Paclitaxel 2volociximab 1tremelimumab 1phenoxodiol 1oregovomab 1olaparib 1lanreotide 1farletuzumab 1enzastaurin 1durvalumab 1cc-486 1catumaxomab 1atezolizumab 1Trastuzumab 1Trabectedin 1Topotecan 1Saline Solution 1Oxaliplatin 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Peritoneal Neoplasms × Octreotide × Clear all
NCT00332696 2011-09-23

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Novartis

Phase 2 Completed
64 enrolled 17 charts
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡